| Literature DB >> 27446310 |
Lei Geng1, Meng Xu1, Ligang Yu1, Jie Li2, Yonggang Zhou1, Yan Wang1, Jiying Chen1.
Abstract
Fungal prosthetic joint infections (PJI) and reports of their clinical investigation are rare. In addition, there has been little evidence regarding the outcome of the two-stage exchange protocol for the treatment of fungal PJI. In order to investigate the risk factors and clinical, microbiological and pathological features of fungal PJIs, as well as the effects of the two-stage exchange protocol on their outcome, the present study analyzed eight retrospective fungal PJI cases, involving four cases affecting the hips and four affecting the knees, between May 2000 and March 2012. In all cases, a cemented spacer saturated with antimicrobials was used during the two-stage exchange protocol, and systematic antifungal agents were administrated during the interim period. The average follow-up duration was 4.4 years. Of the eight cases, six had undergone additional surgery on the infected joint prior to infection with the fungus. Following histological analyses, it was determined that the average number of polymorphonuclear cells in the three patients infected with a fungus was only <5/high power field (HPF; magnification, ×400), and that of the five patients with a hybrid infection was >5/HPF. The average Harris Hip scores or Hospital for Special Surgery knee scores were 43.6 preoperatively and 86 at the last follow-up. The two-stage exchange protocol was performed eight times in seven cases, with a failure rate of 12.5%. The remaining case was successfully treated by resection arthroplasty. The average duration of antifungal agent administration during the interim period in five of the eight cases was 1.5 months. For three of the patients, the duration of antifungal agent administration was prolonged until the c-reactive protein levels were decreased to normal. The average duration of spacer implantation into the joint was 4.3 months. The results of the present study suggested that undergoing surgery on a prosthetic joint may be a potential risk factor for the development of fungal PJI. In addition, infiltration of polymorphonuclear leukocytes into the site of the infection may not occur at the same rate as bacterial PJI. Therefore, a two-stage exchange protocol with implantation of a cement spacer saturated with antimicrobials may be considered an effective therapeutic strategy for the treatment of fungal PJI.Entities:
Keywords: fungi; histopathology; joint arthroplasty; prosthetic joint infection; risk factor
Year: 2016 PMID: 27446310 PMCID: PMC4950886 DOI: 10.3892/etm.2016.3353
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Information regarding the basic condition, chronic disease history, infection phase and microbiological features of the eight patients with a fungal prosthetic joint infection.
| Case no. | Age/gender | Chronic disease history | Site/phase | Fungal species | Other pathogen | Sinus | Positive culture site |
|---|---|---|---|---|---|---|---|
| 1 | 42/M | No | Right hip/delayed phase (9 Mon) | Candida albicans | Acinetobacter lwoffii, | Absence CNS | 6x post-op drainage Intra-op culture |
| 2 | 53/F | Diabetes | Left hip/early phase (1 W) | Candida albicans | SA | Presence | Intra-op culture, Post-op exudate |
| 3 | 43/F | Gallbladder excision | Left hip/late phase (7 Y) | Candida albicans | Enterococcus faecalis | Presence | Sinus intra-op culture |
| 4 | 78/M | No | Left hip/delayed phase (11 Mon) | Candida glabrata | Gram negative bacilli, SA | Presence | Sinus intra-op culture, post-op drainage |
| 5 | 76/F | Hypertension | Right knee/delayed phase (8 Mon) | Mould | CNS | Absence | Intra-op culture |
| 6 | 58/F | No | Left knee/early phase (<1 W) | Candida freyschussii | No | Presence | Intra-op culture |
| 7 | 63/F | No | Left knee/delayed phase (2 Y) | Aspergillus spp. | No | Absence | Intra-op culture |
| 8 | 67/M | Hypertension | Left knee/early phase (3 Mon) | Candida parapsilosis | No | Presence | Post-op exudate |
M, male; F, female; Post-op, postoperative; Intra-op, intraoperative; Mon, month; W, week; Y, year; CNS, coagulase-negative staphylococcus; SA, Staphylococcus aureus.
Figure 1.Preoperative and postoperative X-rays of three cases of a fungal PJI. The X-ray images present the two-stage exchange protocol method for knee and hip joints and the method of resection arthroplasty. (A) Case 1 suffered from fungal PJI of the hip; (B) the prosthesis was removed and the cement joint spacer was implanted. (C) Following treatment with antifungal agents in the interim period, the cement spacer was removed and the prosthesis was reimplantated. (D-F) Case 6 underwent a similar therapeutic program, although the patient suffered from fungal PJI of the knee. (G-I) Case 4 was treated with the cement spacer, but then refused to receive reimplantation of the prosthesis; therefore, (J and K) resection arthroplasty was performed. PJI, prosthetic joint infection.
Treatment and outcome information for the eight patients with a fungal prosthetic joint infection.
| Case No. | Surgery/outcome | Antimicrobial saturated in cement/duration in joint | Antimicrobials/duration | Pre/post-op Harris or HSS | Follow-up duration/results |
|---|---|---|---|---|---|
| 1 | Two-stage revision/success | 4 g Van/40 g/3 Mon | After spacer, Flu/1.5 Mon after revision, Flu/1 Mon | 48/92 | 3.3 Y/No recurrence |
| 2 | Two-stage revision/failure two-stage revision/success | 2nd spacer 4.8 g Van/40 g/3.6 Mon | After 2nd spacer, Flu/1.5 Mon after 2nd revision, Flu/1 Mon | 45/87 | 6.6 Y/No recurrence |
| 3 | Two-stage revision/success | 4 g Van+2 g Mer/40 g/4.5 Mon | Pre-op Flu, Vor/1 Mon after spacer, Flu/4 Mon after revision, Flu/1Mon | 43/86 | 5.1 Y/No recurrence |
| 4 | Spacer implantation/failure resection arthroplasty/success | 4.8 g Van/40 g/6 Mon | After spacer, Flu/3 Mon, Amp/2 Mon after resection arthroplasty Cas/46 days | 37/62 | 2.9 Y/No recurrence before death |
| 5 | Two-stage revision/success | 3 g Van+1 g Mer/40 g/3 Mon | After spacer, Flu/1.5 Mon after revision, Flu/1 Mon | 46/89 | 3.7 Y/No recurrence |
| 6 | Two-stage revision/success | 4 g Van/40 g/3 Mon | After spacer, Flu/1.5 Mon after revision, Cas/1 Mon | 35/91 | 4.7 Y/No recurrence |
| 7 | Two-stage revision/success | 3 g Van+1 g Mer/40 g/7 Mon | After spacer, Flu/6 Mon after revision, Flu/1 Mon | 40/91 | 5.2 Y/No recurrence |
| 8 | Two-stage revision/success | 2 g Van+200 mg Amp/40 g/4 Mon | After spacer, Flu/1.5 Mon after revision, Flu/1 Mon | 55/90 | 4 Y/No recurrence |
Pre-op, preoperative; Post-op, postoperative; Mon, months; W, week; Y, year; Flu, fluconazol; Vor, voriconazole; Amp, Amphotericin B; Cas, caspofungin; Van, vancomycin, Mer, Meropenem; HSS, Hospital for Special Surgery.
Figure 2.Treatment regimes of eight cases of fungal PJI. The yellow boxes represent the surgical procedures undergone by the patients following the primary joint arthroplasty and prior to the diagnosis of fungal PJI, and this was deemed a risk factor of fungal PJI. Red indicates the persistence or recurrence of infection on the joint, whereas green indicates eradication of the infection at ≥2 years follow-up. PJI, prosthetic joint infection; ORIF, open reduction and internal fixation; THA, total hip arthroplasty; TKA, total knee arthroplasty; LCL, lateral collateral ligament.
Figure 3.Histopathological features (hematoxylin and eosin staining; magnification, ×200 in A and B, ×100 in C). Histopathological features of the soft tissue from the infected prosthetic joint of (A) patient 8 who was infected with Candida parapsilosis only, (B) patient 4 who had a hybrid infection with Candida glabrata, gram negative bacilli and Staphylococcus aureus, and (C) patient 5 who was infected with a mould and a coagulase-negative staphylococcus.